Health boards in Wales are required to implement Blueteq HCD in accordance with WHC 2022 032 (March 2023).
The All Wales Blueteq Steering Group will support the roll-out of Blueteq HCD in NHS Wales. The Steering Group is chaired by a Chief Pharmacist and the All Wales Therapeutics and Toxicology Centre (AWTTC) will provide project management support.
Implementation of Blueteq HCD will be phased according to the priorities set out by Welsh Government and the Steering Group. The initial phase will include medicines recommended for use by NICE and AWMSG, which may or may not have an associated commercial arrangement.